LimFlow, Inc. expects the US Food and Drug Administration will approve its percutaneous deep vein arterialization system for patients with advanced critical limb ischemia by the end of 2021.
The LimFlow system installs a stent graft that creates an arteriovenous fistula that moves blood from the diseased tibial artery into the tibial vein to revascularize the patient’s leg below the knee. The system earned a CE mark in 2016 and is available in Europe